Mike Raab Raab
Chief Executive Officer at ARDELYX, INC.
Net worth: 11 M $ as of 2024-03-30
Profile
Michael G.
Raab is currently the President, Chief Executive Officer & Director at Ardelyx, Inc. He is also the Executive Chairman at Amicus Therapeutics, Inc. Additionally, he holds the position of Chairman at TempestTx, Inc. and Tempest Therapeutics, Inc. He is a Director at the California Biomedical Innovation Alliance and a Member of the Biotechnology Innovation Organization.
In his former positions, Mr. Raab served as a Director at Novalar Pharmaceuticals, Inc., Liquidia Technologies, Inc., ZP Opco, Inc., Hyperion Therapeutics, Inc., and Cellgate, Inc. He was also a Director at Novacea, Inc. from 2002 to 2009.
Furthermore, he held positions as a Director at Millendo Therapeutics, Inc., Principal at Bristol Myers Squibb Co., and Principal at Repligen Corp.
Prior to that, he was the Senior Vice President-Therapeutics & GM-Renagel at Genzyme Corp.
from 1999 to 2002.
He was a Partner at NEA Management Co. LLC from 2002 to 2008 and a Partner at New Enterprise Associates LLC from 2002 to 2009.
He also served as a Senior Vice President at Therapeutics, Inc.Mr. Raab obtained his undergraduate degree from DePauw University in 1987.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARDELYX, INC.
0.57% | 2024-04-14 | 1,336,297 ( 0.57% ) | 10 M $ | 2024-03-30 |
| 2024-03-04 | 83,596 ( 0.03% ) | 984 761 $ | 2024-03-30 | |
| 2023-06-14 | 0 ( -.--% ) | - $ | 2024-03-30 |
Mike Raab Raab active positions
| Companies | Position | Start |
|---|---|---|
| AMICUS THERAPEUTICS, INC. | Chairman | 2024-03-03 |
| ARDELYX, INC. | Chief Executive Officer | 2009-02-28 |
| TEMPEST THERAPEUTICS, INC. | Chairman | 2020-12-31 |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Chairman | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Corporate Officer/Principal | - |
California Biomedical Innovation Alliance
 California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Director/Board Member | - |
Former positions of Mike Raab Raab
| Companies | Position | End |
|---|---|---|
Cellgate, Inc.
 Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | Director/Board Member | 2009-06-21 |
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Director/Board Member | 2009-02-02 |
New Enterprise Associates LLC
 New Enterprise Associates LLC Investment ManagersFinance New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich. | Corporate Officer/Principal | 2008-12-31 |
| ░░░ ░░░░░░░░░░ ░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Mike Raab Raab
| DePauw University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| REPLIGEN CORPORATION | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| ARDELYX, INC. | Health Technology |
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Private companies | 14 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Novalar Pharmaceuticals, Inc.
 Novalar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Novalar Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on dental products. The company's OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. The company was founded in 2000 and is headquartered in San Diego, CA. | Health Technology |
Liquidia Technologies, Inc.
 Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
ZP Opco, Inc.
 ZP Opco, Inc. Pharmaceuticals: MajorHealth Technology ZP Opco, Inc. operates as a biopharmaceutical company that develops transdermal delivery technology for therapeutic indications. The company was founded by Peter E. Daddona and Frank D. Stonebanks in 2006 and is headquartered in Fremont, CA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Cellgate, Inc.
Cellgate, Inc. Pharmaceuticals: MajorHealth Technology Progen Pharmaceuticals, Inc. develops biopharmaceuticals products. It is engaged in developing improved drug delivery based on their transporter molecules. The company is headquartered in Redwood City, CA. | Health Technology |
NEA Management Co. LLC
 NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Finance |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
California Biomedical Innovation Alliance
California Biomedical Innovation Alliance BiotechnologyHealth Technology California Biomedical Innovation Alliance provides biomedical advocacy and community services. The private company is based in South San Francisco, CA and has subsidiaries in United States. The CEO of the company is Sara Radcliffe. | Health Technology |
New Enterprise Associates LLC
New Enterprise Associates LLC Investment ManagersFinance New Enterprise Associates LLC is an alternative investment manager. The private company is based in Timonium, MD. The company was founded in 1978 by Chuck Newhall, C. Richard Kramlich. | Finance |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
Therapeutics, Inc.
 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Therapeutics, Inc. is a dermatology CRO that specializes in moving products from concept to commercialization. The private company is based in Reston, VA. The company collaborates with clients to expertly design, create, and execute development programs for FDA registration of topical, oral, and injectable drugs, biologics, and devices. The company's services address all aspects needed for a dermatology CRO, from product development to clinical development and regulatory affairs. | Health Technology |
- Stock Market
- Insiders
- Mike Raab Raab
